Global Generic Drug Affairs

Podcast: Hear how we partner with stakeholders to promote safety and more.

FDA’s Office of Generic Drugs (OGD) ensures, through a scientific and regulatory process, that Americans have access to safe, effective, and high-quality generic drugs. One of the ways OGD supports generic drug regulatory activities is through international engagements. The role of the Global Generic Drug Affairs Team is to lead, coordinate, and manage OGD’s international activities in collaboration with FDA Centers and Offices to advance the overall mission of OGD and FDA.

OGD’s International Activities and Engagements

The OGD Global Generic Drug Affairs team collaborates with strategic partners within and outside FDA to establish internationally-focused programs that promote and protect the American public health. In collaboration with industry, international regulatory agencies, the scientific community, and the public, OGD’s global affairs activities encompass harmonization on scientific and technical recommendations for generic drugs under FDA’s Center for Drug Evaluation and Research (CDER) international harmonization initiatives, regulatory strengthening and reliance, partnerships and information sharing, and setting international standards. Recent collaborations include:

Generic Drug Cluster – One-Year Progress Report – multi-country forum established to address generic drug development globally.
FDA-EMA Parallel Scientific Advice Pilot Program – expansion of the FDA’s and European Medicines Agency’s existing parallel scientific advice for new drugs and biological products.
White Paper: Comparing FDA and EMA Decisions for Market Authorization of Generic Drug Applications covering 2017–2020

Overview of Generic Drug Global Program

Information and Resources

The links to resources below are intended to explain the generic drug program in the U.S. and provide navigational tools for foreign counterparts and information that assists industry in the development of generic drugs and their submission of abbreviated new drug applications (ANDAs).